论文部分内容阅读
目的探讨生长抑素受体(SSTR)在复发和转移性乳腺癌组织中的表达及意义。方法采用免疫组化法检测86例复发和转移性乳腺癌切除转移病灶、转移灶旁组织和正常组织中的SSTR,比较分析3组表达情况;同时将检测结果与这86例患者第1次术后的SSTR表达情况进行比较。结果局部复发癌组织、转移淋巴结组织中SSTR的阳性表达率分别为25.58%、51.16%,高于复发癌旁组织、转移灶旁组织及正常组织中的4.65%、2.33%、0%,差异有统计学意义(P<0.05)。复发和转移性乳腺癌组织中SSTR的阳性表达率为38.37%,低于首次发病时的70.93%,差异有统计学意义(P<0.05)。结论乳腺癌复发和转移癌组织中SSTR阳性表达率明显低于首次发病时;此类患者在应用生长抑素治疗前应尽量检测癌组织中SSTR的表达,以便选择有效辅助治疗方法。
Objective To investigate the expression and significance of somatostatin receptor (SSTR) in recurrent and metastatic breast cancer tissues. Methods Immunohistochemical method was used to detect the expression of SSTR in 86 cases of metastatic and metastatic breast cancer tissues and their adjacent tissues and normal tissues. The expression of SSTR was compared between the 3 groups. The results were compared with those of the 86 cases After the SSTR expression comparison. Results The positive expression rates of SSTR in locally recurred cancer tissues and metastatic lymph nodes tissues were 25.58% and 51.16%, respectively, which were higher than those in para-cancerous tissues, 4.65%, 2.33% and 0% in para-tumor tissues and normal tissues Statistical significance (P <0.05). The positive rate of SSTR in the recurrent and metastatic breast cancer tissues was 38.37%, lower than 70.93% at the first onset, the difference was statistically significant (P <0.05). Conclusion The positive rate of SSTR expression in breast cancer recurrence and metastasis was significantly lower than that of the first onset. Such patients should try to detect the expression of SSTR in cancer tissues before the treatment with somatostatin in order to choose effective adjuvant therapy.